- Home
- ROMA vs IPHA Comparison
ROMA vs IPHA Comparison
Compare ROMA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- IPHA
- Stock Information
- Founded
- ROMA 2018
- IPHA 1999
- Country
- ROMA Hong Kong
- IPHA France
- Employees
- ROMA N/A
- IPHA N/A
- Industry
- ROMA Savings Institutions
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ROMA Finance
- IPHA Health Care
- Exchange
- ROMA Nasdaq
- IPHA Nasdaq
- Market Cap
- ROMA 150.7M
- IPHA 160.1M
- IPO Year
- ROMA 2024
- IPHA 2019
- Fundamental
- Price
- ROMA $3.16
- IPHA $1.82
- Analyst Decision
- ROMA
- IPHA Hold
- Analyst Count
- ROMA 0
- IPHA 2
- Target Price
- ROMA N/A
- IPHA $2.00
- AVG Volume (30 Days)
- ROMA 72.8K
- IPHA 20.4K
- Earning Date
- ROMA 09-25-2025
- IPHA 09-17-2025
- Dividend Yield
- ROMA N/A
- IPHA N/A
- EPS Growth
- ROMA N/A
- IPHA N/A
- EPS
- ROMA N/A
- IPHA N/A
- Revenue
- ROMA $1,568,345.00
- IPHA $14,839,695.00
- Revenue This Year
- ROMA N/A
- IPHA $350.96
- Revenue Next Year
- ROMA N/A
- IPHA $32.92
- P/E Ratio
- ROMA N/A
- IPHA N/A
- Revenue Growth
- ROMA 23.21
- IPHA N/A
- 52 Week Low
- ROMA $0.58
- IPHA $1.29
- 52 Week High
- ROMA $4.66
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ROMA 54.91
- IPHA 36.44
- Support Level
- ROMA $2.50
- IPHA $1.77
- Resistance Level
- ROMA $3.37
- IPHA $1.91
- Average True Range (ATR)
- ROMA 0.30
- IPHA 0.11
- MACD
- ROMA -0.00
- IPHA -0.02
- Stochastic Oscillator
- ROMA 73.41
- IPHA 11.90
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.